期刊文献+

替加环素联合头孢哌酮/舒巴坦治疗泛耐药鲍氏不动杆菌感染临床疗效观察 被引量:33

Clinical therapeutic effect of tigecycline combined with cefoperazone-sulbactam on treatment of pandrug-resistant Acinetobacter baumanniiinfection
原文传递
导出
摘要 目的探讨替加环素联合头孢哌酮/舒巴坦治疗泛耐药鲍氏不动杆菌的临床疗效,为合理选用抗菌药物提供临床依据。方法回顾性分析2012年3-10月3例使用替加环素联合头孢哌酮/舒巴坦治疗泛耐药鲍氏不动杆菌感染重症患者临床资料,对其临床疗效进行评价。结果 3例患者均多次检出泛耐药鲍氏不动杆菌,体外药敏试验提示对替加环素敏感,对头孢哌酮/舒巴坦中介或耐药,选用替加环素联合头孢哌酮/舒巴坦抗感染治疗,1例治愈,2例改善,其中有1例细菌得到清除,疗程8~16d,临床疗效较满意。结论替加环素联合头孢哌酮/舒巴坦对泛耐药鲍氏不动杆菌清除效果尚不明确,但能取得满意的临床疗效。 OBJECTIVE To explore the clinical therapeutic effect of the tigecycline combined with cefoperazone-sulbactam on treatment of pandrug-resistant Acinetobacter baumannii infection so as to guide the reasonable clinical medication.METHODS A total of 3 cases of patients,who used the tigecycline combined with cefoperazone-sulbactam for the treatment of severe pandrug-resistant A.baumannii infections from Mar 2012 to Oct 2012,were retrospectively analyzed,and the therapeutic effects were observed.RESULTS The pandrug-resistant A.baumannii strains were frequently detected in the three patients,and the in vitro drug susceptibility testing indicated that the strains were sensitive to tigecycline,and were intermediate or resistant to cefoperazone-sulbactam.Of the patients treated with the tigecycline combined with cefoperazone-sulbactam,there were 1 case cured and 2 cases improved,one of which was with the bacteria eliminated.The treatment course varied from 8 days to 16 days,and the clinical therapeutic effect was satisfying.CONCLUSION The effect of the tigecycline combined with cefoperazone-sulbactam on the clearance of the pandrug-resistant A.baumannii remains unclear,but the clinical therapeutic effect is satisfying.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2013年第8期1906-1907,共2页 Chinese Journal of Nosocomiology
关键词 替加环素 头孢哌酮 舒巴坦 泛耐药鲍药不动杆菌 临床疗效 Tigecycline Cefoperazone/sulbactam Pandrug-resistant Acinetobacter baumannii Clinical efficacy
  • 相关文献

参考文献3

二级参考文献21

  • 1周颖杰,李光辉.成人及儿童复杂性腹腔内感染的诊断与处理:美国外科感染学会及美国感染病学会指南[J].中国感染与化疗杂志,2010,10(4):241-247. 被引量:240
  • 2Nemec A. Muhidrug resistant Acinetobacterbaumannii[J]. Kiln Mikrobiol Infekc Lek,2008,14(5):162-177.
  • 3Souli M, Galani I. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe[J].Euro Surveill, 2008,13 (47) : 1945.
  • 4Wilcox Mark, Nathwani Dilip, Dryden Matthew. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections[J]. The Journal of Antimicrolbial Chemotheropy, 2004,53 ( 2 ) : 335 -344.
  • 5Moise Pamela A, Forrest Alan, Birmingham Mary C, et al. The efficacy and safety of linezolid as treatment for Staphylo coccus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin [J]. the iournal of antimicrolbial chemotheropy, 2002,50 (6):1017-1026.
  • 6Romanelli RM, Jesus LA, Clemente WT, et al. Outbreak of resistant Acinetobacter baurnannii-mcasures and proposal for prevention and control[J].Braz J Infect Dis, 2009, 13 (5) : 341-347.
  • 7Federico Perez, Andrea M Hujer, KristJne M Hujer, et al Global Challenge of Multidrug Resistant Acinetobacter bau mannii[J]. Antimicrob Agents Chemother, 2007,51(10) 3471- 3484.
  • 8Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baurnannii infections: epidemiology and management [J]. Curr Opin Infect Dis,2010,23(4):332- 339.
  • 9Mastoraki A, Douka E, Kriaras I, et al. Preventing strategy of multidrug resistant Acinetobacter baumanii susceptible only to colistin in cardiac surgical intensive care units[J]. Eur J Cardiothorac Surg, 2008,33 (6) : 1086-1090.
  • 10Falagas M, Fragoulis K, Kasiakou S, et al. Nephrotoxicity of intravenous colistin:a prospective evaluation[J].Int J Antimicrob, 2005,26(6) :504-507.

共引文献864

同被引文献264

引证文献33

二级引证文献157

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部